BrIDGs Projects
BrIDGs projects benefit from certain critical resources needed for the development of new therapeutic agents. Successful applicants receive access to NIH contractors who conduct preclinical synthesis, formulation, pharmacokinetic and toxicology services at no cost to the investigator.
Selected BrIDGs Projects:
- New: Development of Assays to Detect Anti-drug Antibodies Against ACP-501 (Recombinant Human LCAT)
- Development of an Apoa1 Mimetic Peptide for Treatment of Atherosclerosis
- Development of BMP Inhibitors to Treat Blood and Bone Disorders
- New: Development of Nogo Receptor Decoy for the Treatment of Spinal Cord Injury
- Development of P-301 for Chronic Dry Eye
- GMP Manufacture of AAV2-AADC for the Treatment of AADC Deficiency
- New: IND-Enabling Studies for Tumor-Penetrating Microparticles for Pancreatic Cancer
- Long-Acting PTH Analog for Treatment of Patients with Hypoparathyroidism: Support for Pre-clinical Toxicology Studies
- Peripheral CB1 Receptor Antagonist for Therapeutic Use in Metabolic Syndrome
- Pre-Investigational New Drug application Toxicity Studies of Nebulized Propofol Hemisuccinate
- Short Stabilized EPO-Peptide as Side-Effect-Free Therapeutic Agents for Multiple Sclerosis and Acute Brain Trauma
- Small Molecule Treatment for Rheumatoid Arthritis
Social Media Links